Table 4 Congruency of treatment recommendations for skin infections in children with national commensal S. aureus resistance rates
Topical AB | Resistance rate* | First choice systemic AB | Resistance rate* | Second choice systemic AB | Resistance rate* | |
|---|---|---|---|---|---|---|
Impetigo | ||||||
Austria | Fusidic acid | 4.3 | Cephalosporin | No data | Amoxicillin + clavulanic acid | 0 |
Belgium | Fusidic acid | 0 | Flucloxacillin | 0 | Clarithromycin | 16.6 |
France | No guideline | |||||
Hungary | No guideline | |||||
Netherlands | Fusidic acid | 0.5 | Flucloxacillin | 0 | Azithromycin | 5.9 |
Spain | No guideline | |||||
Sweden | Retapamulin | 0 | Cefadroxil | No data | Flucloxacillin | 0 |
UK | Fusidic acid | No data | Flucloxacillin | No data | Clarithromycin | No data |
Cellulitis | ||||||
Austria | No guideline | |||||
Belgium | Flucloxacillin | 0 | No second choice | |||
France | No guideline | |||||
Hungary | No guideline | |||||
Netherlands | Clarithromycin | 4.2 | Azithromycin | 5.9 | ||
Spain | No guideline | |||||
Sweden | No guideline | |||||
UK | Flucloxacillin | No data | Ery/Clarithromycin | No data | ||
Folliculitis and Furuncle | ||||||
Austria | Cephalosporin | No data | Amoxicillin + Clavulanic acid | 0 | ||
Belgium | No guideline | |||||
France | No guideline | |||||
Hungary | No guideline | |||||
Netherlands | No guideline | |||||
Spain | No guideline | |||||
Sweden | No guideline | |||||
UK | Flucloxacillin | No data | Ery/Clarithromycin | No data | ||